A Randomised, Single-blind, Single center, Placebo-controlled, Phase I study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participants.
18 Years - 60 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Nov 2023 by AstraZeneca
No locations available
Participants will subcutaneously receive AZD7503.
Randomised participants will receive AZD7503 subcutaneously.
|Placebo Comparator: Placebo|
Participants will subcutaneously receive placebo.
Randomised participants will receive placebo subcutaneously.